Rupintrivir API Manufacturers
compare suppliers & get competitive offers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Rupintrivir API 223537-30-2?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Rupintrivir. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Rupintrivir
- Synonyms:
- Cas Number:
- 223537-30-2
- DrugBank number:
- DB05102
- Unique Ingredient Identifier:
- RGE5K1Q5QW
General Description:
Rupintrivir, identified by CAS number 223537-30-2, is a notable compound with significant therapeutic applications. Rupintrivir is a rhinovirus 3C protease inhibitor in development for use against human rhinoviral (HRV) infections. Rupintrivir was active against all 48 HRV serotypes tested in a cell protection assay in H1-HeLa cells. It is designed to combat colds caused by rhinovirus.
Indications:
This drug is primarily indicated for: Investigated for use/treatment in viral infection. Its use in specific medical scenarios underscores its importance in the therapeutic landscape.
Mechanism of Action:
Rupintrivir functions by: The 3C protease (3CP) enzyme is central to rhinovirus replication. By binding to and inhibiting this enzyme, AG7088 prevents rhinovirus replication in cells of the respiratory tract and stops cold symptoms developing. This mechanism highlights the drug's role in inhibiting or promoting specific biological pathways, contributing to its therapeutic effects.
Classification:
Rupintrivir belongs to the class of organic compounds known as 2-heteroaryl carboxamides. These are compounds containing a heteroaromatic ring that carries a carboxamide group, classified under the direct parent group 2-heteroaryl carboxamides. This compound is a part of the Organic compounds, falling under the Organic acids and derivatives superclass, and categorized within the Carboxylic acids and derivatives class, specifically within the Carboxylic acid derivatives subclass.
Categories:
Rupintrivir is categorized under the following therapeutic classes: Amino Acids, Amino Acids, Aromatic, Amino Acids, Branched-Chain, Amino Acids, Cyclic, Amino Acids, Essential, Amino Acids, Peptides, and Proteins, Anti-Infective Agents, Antiviral Agents, Enzyme Inhibitors, Protease Inhibitors, Pyrrolidines. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.
Rupintrivir is a type of Anti-infective Agents
Anti-infective agents are a vital category of pharmaceutical active pharmaceutical ingredients (APIs) used in the treatment of various infectious diseases. These agents play a crucial role in combating bacterial, viral, fungal, and parasitic infections. The demand for effective anti-infective APIs has grown significantly due to the increasing prevalence of drug-resistant microorganisms.
Anti-infective APIs encompass a wide range of substances, including antibiotics, antivirals, antifungals, and antiparasitics. Antibiotics are particularly important in fighting bacterial infections and are further categorized into different classes based on their mode of action and target bacteria. Antivirals are designed to inhibit viral replication and are essential in the treatment of viral infections such as influenza and HIV. Antifungals combat fungal infections, while antiparasitics are used to eliminate parasites that cause diseases like malaria and helminthiasis.
The development and production of high-quality anti-infective APIs require stringent manufacturing processes and adherence to regulatory standards. Pharmaceutical companies invest heavily in research and development to discover new and more effective anti-infective agents. Additionally, ensuring the safety, efficacy, and stability of these APIs is of utmost importance.
The global market for anti-infective APIs is driven by factors such as the rising incidence of infectious diseases, the emergence of new and drug-resistant pathogens, and the growing demand for improved healthcare infrastructure. Continuous advancements in pharmaceutical technology and the development of innovative drug delivery systems further contribute to the expansion of this market.
In conclusion, anti-infective agents are a critical category of pharmaceutical APIs that play a pivotal role in treating infectious diseases. Their effectiveness in combating various types of infections makes them essential components in the arsenal of modern medicine.
